ICFSR 2025 task force discusses geroscience trials for healthy aging
The ICFSR Task Force met in March 2025 to discuss geroscience-oriented preclinical and clinical trials for healthy aging, covering aging biomarkers, senotherapeutics, metabolism-targeting medications and non-drug strategies, and named challenges such as validating biomarkers against outcomes like frailty and intrinsic capacity. [1]
Automatic summary · not editorially reviewed
The key findings
The ICFSR Task Force met in March 2025 to discuss geroscience-oriented preclinical and clinical trials aimed at promoting healthy aging. [1]
Identified challenges include validating aging biomarkers against clinical outcomes such as frailty and intrinsic capacity. [1]
The discussions called for improved trial methodologies and harmonization, for example a minimum common dataset, and a paradigm shift among regulatory authorities. [1]
The source at a glance
- Study type / format
- Meeting report abstract
- Population / context
- Participants of the Intrinsic Capacity, Frailty and Sarcopenia Research Task Force meeting in March 2025, discussing geroscience trials.
- Summary based on
- Study abstract
March 2025 meeting on geroscience trials
The Intrinsic Capacity, Frailty and Sarcopenia Research Task Force convened in March 2025. The group discussed geroscience-oriented preclinical and clinical trials aimed at promoting healthy aging. Topics included aging biomarkers in clinical trials, senotherapeutics, metabolism-targeting medications and therapeutic strategies beyond pharmacological approaches. The discussions noted growing interest in and accumulating evidence for geroscience interventions.
Supporting source [1]
Biomarker validation against frailty and capacity
Several future challenges were identified. One is the need for a deeper understanding of the biology of aging. Another is validating aging biomarkers against relevant clinical outcomes, such as frailty and intrinsic capacity. The abstract does not report which biomarkers were discussed or any validation results.
Supporting source [1]
Trial methods, common dataset and regulatory shift
To accelerate innovation, the discussions called for better clinical trial methodologies and harmonization. One example given is defining a minimum common dataset of biological, physiological and clinical factors for geroscience clinical studies. The group also described a need to foster a paradigm shift, particularly among regulatory authorities. These are proposals and identified needs, not validated methods or approved products.
Supporting source [1]
How to interpret this
This is based on the abstract only; the full text was not reviewed. The abstract names topics and challenges but reports no study design, sample, follow-up, results or biomarker validation data. The described needs and proposals are not validated methods or approved products.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Luca Tagliafico, Marco Canevelli, Philipe De Souto Barreto, Matteo Cesari, Luigi Ferrucci, Bruno Vellas, Yves Rolland · doi.org